Sign Out
Based on limited information available under the license of molnupiravir products in emergency situations, no drug interactions were found. There have been no studies on the interaction between molnupiravir and other drugs or in combination with other treatments for the treatment of mild to moderate symptoms of COVID-19 [see Pharmacology: Pharmacokinetics under Actions].
Drug interaction studies: The results from in vitro studies indicate that both molnupiravir and NHC are not inhibitors of CYP1A2, 2B6, 2C8, 2C9, 2C19, 2D6, and 3A4, as well as non-inhibitors of OATP1B1, OATP1B3, OCT1, OCT2, OAT1, OAT3, MATE1, MATE2K, MRP2, MDR1, and BCRP. It does not induce CYP1A2, 2B6, and 3A4 enzymes. However, drug interaction has not been evaluated in combination with molnupiravir or in combination with other treatments for the treatment of mild to moderate symptoms of COVID-19.
Continue with Google